Results 41 to 50 of about 349 (107)

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers ...
Stefan D. Anker, Linong Ji, Tammy Kindel, Andrew J. S. Coats, Dike Ojji, Adriana Puente Barragán, Peter Rossing, Shelley Zieroth, Shaaf Ahmad, Shariq Usman, Geeta Appannah, Alison L. Bailey, Ahmed Bennis, Andrea Brandao, Javed Butler, Melanie J. Davies, Lubomira Fabryova, Yuan‐Lin Guo, Hidetaka Itoh, Uday M. Jadhav, Carel W. Le Roux, Fausto J. Pinto, Julio Rosenstock, Banshi Saboo, Hani Sabbour, Mangesh Tiwaskar, Karol E. Watson, Kwang Wei Tham, Fernando Stuardo Wyss, Walter P. Abhayaratna, William T. Abraham, Wael Al Mahmeed, Alessia Argirò, John J. Atherton, Danielle Belardo, Raquel Campuzano, Nandini Chatterjee, Marc‐André Cornier, Sarah Davies, Clemencia de Rueda Panadero, Anastase Dzudie, Ty J. Gluckman, Muhammad Shahzeb Khan, Kamlesh Khunti, Yuri Lopatin, Zhiyi Ma, Okechukwu S. Ogah, Abraham Oomman, Emilio S. Peralta Lopez, Ping Li, Paul Poirier, Julie Redfern, Giuseppe M. C. Rosano, Donna Ryan, Amit Saraf, Sameh Shaheen, Subodh Verma, Stephan von Haehling, Martha Gulati, Naveed Sattar, Jose Luis Zamorano   +60 more
wiley   +1 more source

Changes in Eating Behaviour During Treatment With Obesity Medications

Clinical Obesity, Volume 16, Issue 1, February 2026.
ABSTRACT Obesity is a chronic, relapsing disease influenced by biological, environmental and behavioural factors. Pharmacological therapies have demonstrated substantial effects in weight loss, appetite suppression and modulation of food‐related thoughts; however, the long‐term effects of medications and eating behaviours across treatment phases ...
Ming Chuen Chong, Tak Ying Louise Ko, Philippus L. le Roux, Carel W. le Roux   +3 more
wiley   +1 more source

Central nervous system pathways targeted by amylin in the regulation of food intake [PDF]

Amylin is a peptide hormone co-released with insulin from pancreatic β-cells during a meal and primarily serves to promote satiation. While the caudal hindbrain was originally implicated as a major site of action in this regard, it is becoming ...
Le Foll, Christelle; https://orcid.org/, Hankir, Mohammed K   +1 more
core   +1 more source

Uus kaalu langetav kombinatsiooniravim CagriSema [PDF]

Eesti Arst 2026; 105(6–7):329 ...
Linnamägi, Eeva Liisa
core   +1 more source

Cagrilintide-Semaglutide in Adults with Overweight or Obesity

In the REDEFINE 1 trial, Garvey and colleagues (Aug. 14 issue)1 report the efficacy of combination therapy with cagrilintide and semaglutide (known as CagriSema) in patients with overweight or obesity who did not have diabetes.
Fogacci F, Cicero AFG
core   +1 more source

Emerging Pharmacotherapies for Obesity:A Systematic Review [PDF]

The history of anti-obesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the conviction that excess body weight signifies a lack of willpower.
Valenzuela-Vallejo, Laura, Kokkorakis, Michail; id_orcid, Rifai, Jana Al, Chakhtoura, Marlene, Ghezzawi, Malak, Mantzoros, Christos S., Rhayem, Caline   +6 more
core   +1 more source

Obesity Pharmacotherapy Beyond Weight Loss: Incretin-Based Therapies, Maintenance, and the Role of Family Physicians

According to the American Association of Clinical Endocrinology, obesity is a chronic disease driven by complex genetic, environmental, metabolic, and neuroregulatory factors that disrupt energy homeostasis and promote excess adiposity (1).
I Mohamud
core   +1 more source

"CagriSema: Emerging Data on a New Treatment Option for Patients with Diabetes"

Journal of pharmacology & clinical research, 2023
openaire   +1 more source

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

OBJECTIVE: To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients.
Tian, Haoming, Khunti, Kamlesh, Hao, Qiukui, Florez, Ivan D, Vandvik, Per Olav, Guyatt, Gordon H, Zhu, Zhiming, Zhang, Haojie, Jia, Qingyi, Mao, Yunhe, Shi, Qingyang, Agarwal, Arnav, Widyahening, Indah S, Sun, Xiaodong, Li, Sheyu, Gao, Yiyuan, Li, Jing, Nong, Kailei, Agoritsas, Thomas, Du, Heyue, Wang, Yang, Fan, Qinlin, Pan, Xiaohui, Xie, Xinran, Liu, Tianyou, Le Roux, Carel W, Sun, Feng, Wang, Chaoyang, MD, Zou, Xinyu   +28 more
core  

Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives. [PDF]

Front Endocrinol (Lausanne)
Mehetre KN, Dawane JS.
europepmc   +1 more source